Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Testosterone replacement therapy and the risk of prostate cancer. Is there a link?

International Journal of Impotence Research volume 18, pages 323–328 (2006)Cite this article

Abstract

Substantial evidence supports the value of testosterone replacement therapy (TRT) in improving quality of life in men with proven aging male syndrome (AMS). Benefits of TRT include improved bone mineral density, reduced fracture risk, increased muscle mass, and improved mood, sense of well being, and libido, among others. There is currently a heated debate about the theoretical association between TRT and the initiation, progression, and aggressiveness of prostate cancer; however, this link has not been uniformly studied, and any results have been contradictory and nonconclusive. Although no clear evidence links TRT to prostate cancer, the possibility of increasing the risk of a clinical manifestation of a latent pre-existing malignancy can influence the decision about TRT use. Current recommendations are to exclude prostate cancer before initiating TRT in men over age 40 and to closely monitor men in the first year of testosterone replacement, followed by observation in subsequent years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wilson JD . The Pharmacological Basis of Therapeutics. In: Hardman JG, Limbird LE (eds) Androgens 10th edn. McGraw-Hill: New York, 2001, pp. 1441–1498.

    Google Scholar 

  2. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 2005; 102: 1151–1156.

    Article  CAS  Google Scholar 

  3. Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 281–286.

    Article  CAS  Google Scholar 

  4. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098.

    Article  CAS  Google Scholar 

  5. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871–876.

    Article  CAS  Google Scholar 

  6. Huggins C, Hodges CV . Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.

    CAS  Google Scholar 

  7. Morales A . Androgen replacement therapy and prostate safety. Eur Urol 2002; 41: 113–120.

    Article  CAS  Google Scholar 

  8. Litvinov IV, Antony L, Isaacs JT . Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate 2004; 61: 299–304.

    Article  CAS  Google Scholar 

  9. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731, Notes: CORPORATE NAME: Baltimore Longitudinal Study of Aging.

    Article  CAS  Google Scholar 

  10. Deslypere JP, Vermeulen A . Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59: 955–962.

    Article  CAS  Google Scholar 

  11. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589–598.

    Article  CAS  Google Scholar 

  12. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ . Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004; 61: 124–131.

    Article  CAS  Google Scholar 

  13. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  CAS  Google Scholar 

  14. Bonkhoff H, Stein U, Remberger K . Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25: 42–46.

    Article  CAS  Google Scholar 

  15. Bonkhoff H, Stein U, Remberger K . The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994; 24: 114–118.

    Article  CAS  Google Scholar 

  16. Morgentaler A, Bruning 3rd CO, DeWolf WC . Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904–1906.

    Article  CAS  Google Scholar 

  17. Behre HM, Bohmeyer J, Nieschlag E . Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxford) 1994; 40: 341–349.

    Article  CAS  Google Scholar 

  18. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD . Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922–926.

    PubMed  Google Scholar 

  19. Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312–1315.

    Article  CAS  Google Scholar 

  20. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670–1675.

    Article  Google Scholar 

  21. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005; 47: 308–312.

    Article  CAS  Google Scholar 

  22. Furuya Y, Nozaki T, Nagakawa O, Fuse H . Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocr J 2002; 49: 85–90.

    Article  Google Scholar 

  23. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS . Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18(4): 847–853.

    Article  CAS  Google Scholar 

  24. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 1410–1416.

    CAS  PubMed  Google Scholar 

  25. Zagars GK, Pollack A, von Eschenbach AC . Serum testosterone—a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997; 49: 327–334.

    Article  CAS  Google Scholar 

  26. Mikkola AK, Aro JL, Rannikko SA, Salo JO . Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group. Prostate 1999; 39: 175–181.

    Article  CAS  Google Scholar 

  27. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B . Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76: 45–48.

    CAS  Google Scholar 

  28. Kubricht 3rd WS, Williams BJ, Whatley T, Pinckard P, Eastham JA . Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology 1999; 54: 1035–1038.

    Article  Google Scholar 

  29. Mohler JL, Gaston KE, Moore DT, Schell MJ, Cohen BL, Weaver C et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004; 171: 2277–2280.

    Article  CAS  Google Scholar 

  30. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502–1510.

    Article  CAS  Google Scholar 

  31. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503–510.

    Article  CAS  Google Scholar 

  32. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology 2001; 58: 994–998.

    Article  CAS  Google Scholar 

  33. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW . Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001; 57: 1100–1104.

    Article  CAS  Google Scholar 

  34. Philip J, Dutta Roy S, Ballal M, Foster CS, Javle P . Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer? BJU Int 2005; 95: 969–971.

    Article  Google Scholar 

  35. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005; 173: 1930–1934.

    Article  Google Scholar 

  36. Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R et al. Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. Prostate 2005; 64: 240–245.

    Article  Google Scholar 

  37. Agarwal PK, Oefelein MG . Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533–536.

    Article  CAS  Google Scholar 

  38. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am 2001; 28: 555–565.

    Article  CAS  Google Scholar 

  39. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125–127.

    Article  CAS  Google Scholar 

  40. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341–1345.

    CAS  PubMed  Google Scholar 

  41. Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS . The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002; 89: 710–713.

    Article  CAS  Google Scholar 

  42. Ribeiro M, Ruff P, Falkson G . Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997; 20: 605–608.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora,, CO, USA

    A Barqawi & E D Crawford

Authors
  1. A Barqawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E D Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Barqawi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barqawi, A., Crawford, E. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?. Int J Impot Res 18, 323–328 (2006). https://doi.org/10.1038/sj.ijir.3901418

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901418

Keywords

This article is cited by

Search

Advanced search

Quick links